The recent market report from Technavio predicts that the U.S. clinical immunoassay analyzer market will grow at a CAGR of 6.04 percent during the period 2016-2020. To calculate market size, the report considered the revenue generated from the sales of these analyzers.
The market is driven by the increasing need for quality immunoassay analyzers to perform testing for cancer markers, diagnosis of infectious diseases such as human immunodeficiency virus (HIV) and hepatitis, cardiac analysis, therapeutic drug monitoring and allergy testing. Today’s automated analyzers can efficiently organize testing to achieve maximum throughput. They can process multiple samples simultaneously with unique diluent and ratio requirements, and provide multiple results from one sample. They can initiate the precise and proper testing from an entire menu of assays, applying proper diluents – all without requiring laboratory personnel for sorting and organizing.
The Technavio report covers the landscape and growth prospects of the market over the coming years. The main findings are as follows:
- The rising demand for next-generation immunodiagnostics that provide high-quality, reliable test results for patients and clinicians is a key driver of market growth.
- The high cost of upgrading is a major challenge that will impact the growth of this market.
- Latest research is focused on developing paper-based electrochemical immunoassay devices that can be used for point-of-care testing (POCT) and diagnosis.
The report identifies the key players in the market as Abbott Diagnostics, bioMérieux, Roche Diagnostics, Siemens and Beckman Coulter. Other prominent vendors include Randox Laboratories, Thermo Fisher Scientific, Olympus, Quidel, and DRG International.